MHCII restriction demonstrates B cells have very limited capacity to activate tumour-specific CD4⁺ T cells in vivo

References

• Wennhold K,Thelen, M, Lehmann, J, Schran, S, Preugszat, E, Garcia-Marquez, M, Lechner, A, Shimabukuro-Vornhagen, A, Ercanoglu, MS, Klein, F, et al. CD86(+) antigen-presenting B cells are increased in Cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol Res. 2021;9(9):1098–8.
   PubMed Web of Science ®Google Scholar
• Wennhold K, Weber TM, Klein-Gonzalez N, Thelen M, Garcia-Marquez M, Chakupurakal G, Fiedler A, Schlösser HA, Fischer R, Theurich S, et al. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget. 2017;8(17):27740–27753. doi:10.18632/oncotarget.7720.
   PubMedGoogle Scholar
• Phan TG, Amesbury M, Gardam S, Crosbie J, Hasbold J, Hodgkin PD, Basten A, Brink R. B cell receptor–independent stimuli trigger immunoglobulin (ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med. 2003;197(7):845–60. doi:10.1084/jem.20022144.
   PubMed Web of Science ®Google Scholar
• Guy TV, Terry AM, Bolton HA, Hancock DG, Zhu E, Brink R, McGuire HM, Shklovskaya E, de St Groth BF. Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity. Oncotarget. 2016;7(21):30211–29. doi:10.18632/oncotarget.8797.
   PubMedGoogle Scholar
• Shklovskaya E, Terry AM, Guy TV, Buckley A, Bolton HA, Zhu E, Holst J, Fazekas de St Groth B. Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. Immunol Cell Biol. 2016;94(6):593–603. doi:10.1038/icb.2016.14.
   PubMed Web of Science ®Google Scholar
• Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EKM, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207(3):651–67. doi:10.1084/jem.20091921.
   PubMed Web of Science ®Google Scholar
• Shinkai Y, Lam, KP, Oltz, EM, Stewart, V, Mendelsohn, M, Charron, J, Datta, M, Young, F, Stall, AM, Alt, FW. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855–867. doi:10.1016/0092-8674(92)90029-C.
   PubMed Web of Science ®Google Scholar
• Seder RA, Paul WE, Davis MM, Fazekas de St Groth B. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med. 1992;176(4):1091–1098. doi:10.1084/jem.176.4.1091.
   PubMed Web of Science ®Google Scholar
• Holst J, Szymczak-Workman AL, Vignali KM, Burton AR, Workman CJ, Vignali DAA. Generation of T-cell receptor retrogenic mice. Nat Protoc. 2006;1(1):406–17. doi:10.1038/nprot.2006.61.
   PubMed Web of Science ®Google Scholar
• Shklovskaya E, Roediger B, Fazekas de St Groth B. Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J Immunol. 2008;181(1):418–30. doi:10.4049/jimmunol.181.1.418.
   PubMed Web of Science ®Google Scholar
• Brooks A, Hartley S, Kjer-Nielsen L, Perera J, Goodnow CC, Basten A, McCluskey J. Class II-restricted presentation of an edogenously derived immunodominant T-cell determinant of hen egg lysozyme. Proc Natl Acad Sci U S A. 1991;88(8):3290–3294. doi:10.1073/pnas.88.8.3290.
   PubMed Web of Science ®Google Scholar
• Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE. Adoptive transfer of tumor reactive B cells confers host T-Cell immunity and tumor regression. Clin Cancer Res. 2011;17(15):4987–4995. doi:10.1158/1078-0432.CCR-11-0207.
   PubMed Web of Science ®Google Scholar
• Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol. 2000;164(5):2338–2346. doi:10.4049/jimmunol.164.5.2338.
   PubMed Web of Science ®Google Scholar
• Archambault AS, Carrero JA, Barnett LG, McGee NG, Sim J, Wright JO, Raabe T, Chen P, Ding H, Allenspach EJ, et al. Cutting edge: conditional MHC class II expression reveals a limited role for B cell antigen presentation in primary and secondary CD4 T cell responses. J Immunol. 2013;191(2):545–550. doi:10.4049/jimmunol.1201598.
   PubMed Web of Science ®Google Scholar
• Laumont CM, Banville AC, Gilardi M, Hollern DP, Nelson BH. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat Rev Cancer. 2022;22(7):414–430. doi:10.1038/s41568-022-00466-1.
   PubMed Web of Science ®Google Scholar
• Linette GP, Carreno BM. On the twentieth anniversary of dendritic cell vaccines - riding the next wave. Cancer Res. 2022;82(6):966–968. doi:10.1158/0008-5472.CAN-21-4440.
   PubMed Web of Science ®Google Scholar
• Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63:2836–43.
   PubMed Web of Science ®Google Scholar
• Kim SK, Nguyen Pham T-N, Nguyen Hoang TM, Kang H-K, Jin C-J, Nam J-H, Chung S-Y, Choi SJN, Yang D-H, Kim Y-K, et al. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 2009;88(11):1113–1123. doi:10.1007/s00277-009-0721-y.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006–4016. doi:10.4049/jimmunol.0903009.
   PubMed Web of Science ®Google Scholar
• Pham CD, Woo M-Y, Kim Y-S, Park S, Kwon M-H. An anti-nucleic acid antibody delivers antigen to the cross-presentation pathway in dendritic cells and potentiates therapeutic antitumor effects. J Immunol. 2012;189(12):5755–63. doi:10.4049/jimmunol.1200804.
   PubMed Web of Science ®Google Scholar
• Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang H-G, Yan J, et al. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J Immunol. 2013;190(11):5588–5599. doi:10.4049/jimmunol.1203216.
   PubMed Web of Science ®Google Scholar
• Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med. 1994;179(1):125–134. doi:10.1084/jem.179.1.125.
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and fas (CD95)-ligands modulated by the B cell antigen receptor. Cell. 1996;87(2):319–29. doi:10.1016/S0092-8674(00)81349-5.
   PubMed Web of Science ®Google Scholar
• Fulcher DA, Lyons AB, Korn SL, Cook MC, Koleda C, Parish C, Fazekas de St Groth B, Basten A. The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med. 1996;183(5):2313–28. doi:10.1084/jem.183.5.2313.
   PubMed Web of Science ®Google Scholar
• Bikah G, Pogue-Caley RR, McHeyzer-Williams LJ, McHeyzer-Williams MG. Regulating T helper cell immunity through antigen responsiveness and calcium entry. Nat Immunol. 2000;1(5):402–12. doi:10.1038/80841.
   PubMed Web of Science ®Google Scholar